These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 21740829)

  • 1. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
    Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
    Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
    Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL;
    Am J Cardiol; 2009 Dec; 104(11):1484-9. PubMed ID: 19932779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
    Böhm M; Baumhäkel M; Teo K; Sleight P; Probstfield J; Gao P; Mann JF; Diaz R; Dagenais GR; Jennings GL; Liu L; Jansky P; Yusuf S;
    Circulation; 2010 Mar; 121(12):1439-46. PubMed ID: 20231536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telmisartan, ramipril, or both in patients at high risk for vascular events.
    ; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
    N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
    Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
    Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telmisartan for the management of patients at high cardiovascular risk.
    Ruilope LM
    Curr Med Res Opin; 2011 Aug; 27(8):1673-82. PubMed ID: 21718097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.
    Sleight P
    J Hypertens Suppl; 2009 Jul; 27(5):S23-9. PubMed ID: 19587551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).
    Redon J; Mancia G; Sleight P; Schumacher H; Gao P; Pogue J; Fagard R; Verdecchia P; Weber M; Böhm M; Williams B; Yusoff K; Teo K; Yusuf S;
    J Am Coll Cardiol; 2012 Jan; 59(1):74-83. PubMed ID: 22192672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
    Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
    Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
    Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
    Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Sleight P
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
    Kappert K; Böhm M; Schmieder R; Schumacher H; Teo K; Yusuf S; Sleight P; Unger T;
    Circulation; 2012 Aug; 126(8):934-41. PubMed ID: 22829023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan in high-risk cardiovascular patients.
    Weber MA
    Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk.
    Liebson PR; Amsterdam EA
    Prev Cardiol; 2009; 12(1):43-50. PubMed ID: 19301691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
    Williams B; Lacourcière Y; Schumacher H; Gosse P; Neutel JM
    J Hum Hypertens; 2009 Sep; 23(9):610-9. PubMed ID: 19225530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
    Unger T
    Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.